reports
Kane Biotech Inc: 2 directors
Two Directors at Kane Biotech Inc bought/subscribed to 2,600,000 shares at 0.100CAD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Kane to Host Investor Webinar – What Kane has in Store for 2025 Includ...
Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology Thursday, January 23rd, 2025 at 4:15pm Eastern Time WINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday, January 23, 2025 at 4:15pm Eastern Time. Participants can register for the webinar by using this link: Marc Edwards, President and CEO, along with Dr. Robert Huizinga, Executive Chairman will update investors as to what they should expect in 2025, building on th...
Kane Biotech Announces First Closing of Private Placement Offering and...
Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has completed the first closing of its previously announced non-brokered private placement offering (the “Offering”) of common shares of the Company (“Shares”). At the first closing Kane issued 12,750,000 Shares at a price of $0.10 per...
Kane Biotech Announces $3,000,000 Private Placement Offering
Kane Biotech Announces $3,000,000 Private Placement Offering WINNIPEG, Manitoba, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it intends to undertake a non-brokered private placement offering of up to 30,000,000 common shares of the Company (each a “Share”) at a price of $0.10 per Share for aggregate proceeds of up to $3,000,000 (the “Offering”). The proceeds from the Offering will be used for working capital and general corporate purposes. “We are continuing to build shareholder value as indicated i...
Kane Biotech Announces Third Quarter 2024 Financial Results
Kane Biotech Announces Third Quarter 2024 Financial Results Company Records First Commercial Sale of revyve™ Wound Gel WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial results. Third Quarter 2024 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Product sales for the three months ended September 30, 2024 was $597,677 compared to $3,631 in the three months ended September 30, 2023. During the third quart...
Kane Biotech Announces Change in US Distribution Partner for revyve™ A...
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces today that BioStem Technologies Inc. (“BioStem”), has recently signed a Letter of Intent to acquire commercial stage products and development technologies from the Company’s current U.S. distributor, ProgenaCare Global LLC (“P...
Kane Biotech to Release Third Quarter 2024 Financial Results on Novemb...
Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024 Conference Call to be held on December 3, 2024 WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results after market close on Thursday, November 28, 2024. Kane Biotech management will host a conference call at 4:30 p.m. ET on December 3, 2024 to review the financial results and discuss business developments in the period. Participants must register for the call using the following :...
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial...
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the Company to immediately start promoting and selling this product in Canada. “We are excited to bring this much needed product to Canada,” said Marc Edwards, President & CEO. “Congratulations to the Kane Biotech team for achievin...
Kane Biotech Provides Investor Update Following FB Dermatology Acquisi...
Kane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement President & CEO Marc Edwards and Executive Chair Dr. Robert Huizinga Discuss This Strategic Opportunity WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech”) announces today that President & CEO, Marc Edwards and Dr. Robert Huizinga, Executive Chair of Kane Biotech have released a video outlining the details and benefits to Kane Biotech and its investors of the FB Dermatology S.R.L. (“FB Dermatology”) transaction which the Co...
Kane Biotech Announces Agreement to Acquire FB Dermatology
Kane Biotech Announces Agreement to Acquire FB Dermatology Transaction will Strengthen Kane’s Wound Care and Dermatology Portfolio and Expand Global Commercial Reach WINNIPEG, Manitoba, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech”) announces today that it has entered into a binding term sheet (the “Term Sheet”) setting out the key terms and conditions relating to the acquisition of all of the issued and outstanding shares (the “Purchased Shares”) of FB Dermatology S.R.L. (“FB Dermatology”), incorporated under the laws of It...
Kane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to ...
Kane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to Ukraine WINNIPEG, Manitoba, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it is donating 2,000 ounces of revyve™ Antimicrobial Wound Gel to the Ukraine medical relief effort. The product will be used to assist in the healing of severe and chronic wounds that tens of thousands of Ukrainian casualties have suffered as a result of the devasting effects of war. “I am humbled by the prospect of assisting the people of Ukraine in their time of...
Kane Biotech Announces Exclusive Distribution Agreement With XSONX
Kane Biotech Announces Exclusive Distribution Agreement With XSONX WINNIPEG, Manitoba, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed an exclusive five year distribution agreement with XSONX LLC (“XSONX”) for Kane to distribute XSONX’s Wound Hygiene System in Canada, Australia, New Zealand and the Gulf Cooperation Council (GCC) Countries (the “Territories”). The XSONX Wound Hygiene System is a cordless vibrational debridement tool which safely cleans and debrides chronic and contaminated wounds. More i...
Kane Biotech to Participate in a Multinational Corporate Collaboration...
Kane Biotech to Participate in a Multinational Corporate Collaboration Project WINNIPEG, Manitoba, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to $75,000 in funding through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to collaborate on a research and development project with a multinational corporate partner. The goal of the collaboration project is to develop a Proof-of Concept for its DispersinB® Wound Gel. Over ...
Kane Biotech Announces Attendance at Upcoming Wound Care Conferences
Kane Biotech Announces Attendance at Upcoming Wound Care Conferences WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the Company will be showcasing its revyve™ Antimicrobial Wound Gel and revyve™ Antimicrobial Wound Gel Spray products at the following wound care conferences: Symposium on Advanced Wound Care (SAWC) (October 2-5, 2024 in Las Vegas Nevada) where Kane will be presenting research on the antibiofilm properties and compatibility with different dressings of revyve™ Ant...
Kane Biotech Announces Exercise of Warrants
Kane Biotech Announces Exercise of Warrants WINNIPEG, Manitoba, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the exercise of an aggregate of 5 million warrants at an exercise price of $0.10 per common share for total proceeds of $500,000. “The shares are being held by some long-term supporters of Kane,” said Marc Edwards, President & CEO. The proceeds from these warrant exercises will be used for general working capital purposes. About Kane Biotech Kane Biotech Inc. is a biotechnology company engaged in the...
Kane Biotech Announces Second Quarter 2024 Financial Results
Kane Biotech Announces Second Quarter 2024 Financial Results Company Realizes $10.4M Gain on the Sale of STEM WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its second quarter 2024 financial results. The second quarter 2024 financial results reflect the closing of the sale of STEM which took place on April 12, 2024. The Company recorded a gain of $10,359,882 on this transaction which is offset by income tax loss carry forwards for income tax purposes. Second Quarter 2024 Financ...
Kane Biotech Announces new DispersinB® Publication in Pathogens and Co...
Kane Biotech Announces new DispersinB® Publication in Pathogens and Conference Presentations WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the publication of a new review article on DispersinB® in the journal Pathogens. Pathogens is an international, peer-reviewed, open access journal focusing on pathogens and pathogen-host interactions. The article, entitled “Aggregatibacter actinomycetemcomitans Dispersin B: The Quintessential Antibiofilm Enzyme,” is first authored by Dr. Jeffrey B. Kaplan, the dis...
Kane Biotech Announces Distribution Agreement with Qatar Datamation Sy...
Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve™ Antimicrobial Wound Gel Company’s Second Distribution Agreement in Middle East WINNIPEG, Manitoba, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution agreement with Qatar Datamation Systems (“QDS”) for its revyve™ Antimicrobial Wound Gel in the Qatar wound care market. “Kane continues its global commercialization of revyve™ with its second distribution agreement in the Middle Eas...
Kane Biotech to Release Second Quarter 2024 Financial Results on Augus...
Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will announce its second quarter 2024 financial results after market close on Thursday, August 29, 2024. Kane Biotech management will host a conference call at 4:30 p.m. ET on August 29, 2024 to review the financial results and discuss business developments in the period. Participants must register for the call using this : It is recommended that you join 10 minutes ...
Kane Biotech Announces Distribution Agreement with Razan Medical Tradi...
Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel Company’s First Distribution Agreement in Middle East WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution agreement with Razan Medical & Surgical Equipment Trading LLC (“Razan Medical” or “Razan Medical Trading”) for its revyve™ Antimicrobial Wound Gel in the United Arab Emirates (UAE) wound care market. “At Razan Medical, we are dedicated ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.